MK-2206 dihydrochloride MK2206 CAS: 1032350-13-2

CAS NO: 1032350-13-2
MK-2206 dihydrochloride MK2206
Chemical Name: MK-2206 2HCl
Molecular Formula: C25H22ClN5O
Formula Weight: 443.94
CAS No.: 1032350-13-2
Description Review
Description

MK-2206 dihydrochloride is a potent and selective inhibitor of AKT1/2/3, which are protein kinases that play a critical role in cell growth and survival. It is used primarily in cancer treatment, where it has shown promising results in preclinical trials.

Chemical name: 8-[4-(1-Amino-1-methylethyl)phenyl]-9-phenyl-2H-benzo[h]chromen-2-one dihydrochloride Molecular formula: C32H33N2OCl2 Formula weight: 581.54 g/mol CAS No: 1032350-13-2

Top ten keywords and synonyms from Google search:

  1. AKT inhibitor
  2. Cancer treatment
  3. Phosphatidylinositol -3 kinase (PI3K) pathway
  4. Apoptosis
  5. Tumor growth
  6. Oncology
  7. Molecular targeted therapy
  8. Cell signaling
  9. Anticancer agent
  10. Anti-proliferative agent

Health benefits of this product include its ability to inhibit tumor growth and induce apoptosis in cancer cells. It has also been shown to have anti-proliferative effects on various types of cancer cells. Preclinical studies have demonstrated the potential for MK-2206 to work synergistically with other anticancer agents, enhancing their effectiveness.

MK-2206 dihydrochloride works by inhibiting the AKT signaling pathway, which is activated in many cancers and is involved in regulating cell proliferation, survival, and metabolism. By blocking this pathway, MK-2206 can induce apoptosis in cancer cells and inhibit tumor growth.

Safety is an important consideration when using any therapeutic agent. Preclinical studies have shown that MK-2206 dihydrochloride has a favorable safety profile, with no evidence of significant toxicity or adverse effects at therapeutic doses. However, as with any drug, careful monitoring and dose adjustment may be needed to minimize the risk of side effects.

Common side effects associated with MK-2206 dihydrochloride include fatigue, nausea, diarrhea, and rash. These side effects are generally mild and self-limiting, and most patients tolerate treatment well.

Dosing information for MK-2206 dihydrochloride varies depending on the patient's age, weight, and medical history. It is typically administered orally once daily, and the recommended dose range is 60-600 mg/day.

In conclusion, MK-2206 dihydrochloride is a promising anticancer agent that works by inhibiting the AKT signaling pathway. It has been shown to have anti-proliferative and pro-apoptotic effects on cancer cells, making it a potential candidate for molecular targeted therapy in cancer treatment. While it has a favorable safety profile, careful monitoring and dose adjustment may be necessary to minimize the risk of side effects.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us